Correlation of microrna-372 upregulation with poor prognosis in human glioma

Diagnostic Pathology

Guodong Gao³  Shiming He³  Guangbin Cui²  Hongjuan Liang³  Tianbo Jin¹  Yanyang Tu⁴  Zhiguo Zhang³  Gang Li³ 

[1] National Engineering Research Center for Miniaturized Detection Systems, School of Life Sciences, Northwest University, Xi’an, 710069, China;Department of Radiology, Tangdu hospital, the Fourth Military Medical University, Xi’an, 710038, China;Department of Neurosurgery, Tangdu hospital, the Fourth Military Medical University, No. 569, Xinsi Road, Xi’an, 710038, China;Department of Clinical Experimental Surgery, Tangdu hospital, the Fourth Military Medical University, Xi’an, 710038, China

关键词: Prognosis;    Real-time quantitative RT-PCR assay;    Glioma;    miR-372;   

Others  :  807711
DOI  :  10.1186/1746-1596-8-1

 received in 2012-11-16, accepted in 2013-01-02,  发布年份 2013

【 摘 要 】

MicroRNA-372 (miR-372) acts as either an oncogenic miRNA or an anti-oncomiR in various human malignancies. However, its roles in gliomas have not been elucidated. To address this problem, we here detected miR-372 expression in human gliomas and non-neoplastic brain tissues by real-time quantitative RT-PCR assay. The association of miR-372 expression with clinicopathological factors or prognosis of glioma patients was also statistically analyzed. As the results, miR-372 expression levels were significantly upregulated in glioma tissues compared to the corresponding non-neoplastic brain tissues (P<0.001). In addition, the high miR-372 expression was significantly associated with the advanced pathological grade (P=0.008) and the low Karnofsky performance score (KPS) of glioma patients (P=0.01). Moreover, the overall survival of patients with high miR-372 expression was dramatically shorter than those with low miR-372 expression (P<0.001). Furthermore, multivariate Cox regression analysis indicated that miR-372 expression was an independent prognostic factor for glioma patients (P=0.008). More importantly, subgroup analyses according to tumor pathological grade revealed that the cumulative overall survival of glioma patients with advanced pathological grades was significantly worse for high miR-372 expression group than for low miR-372 expression group (P<0.001), but no significant difference was found for patients with low pathological grades (P=0.08). Taken together, these data offer the convincing evidence for the first time that miR-372 may act as an oncogenic miRNA in gliomas and represent a potential regulator of aggressive development and a candidate prognostic marker for this malignancy, especially for advanced tumors with high pathological grades.

Virtual slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1707761328850011 webcite

【 授权许可】

   
2013 Li et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Masui K, Cloughesy TF, Mischel PS: Molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol 2012, 38:271-291.
• [2]Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114:97-109.
• [3]Catuogno S, Esposito CL, Quintavalle C, Condorelli G, de Franciscis V, Cerchia L: Nucleic acids in human glioma treatment: innovative approaches and recent results. J Signal Transduct 2012, 2012:735135.
• [4]Gömöri E, Pál J, Kovács B, Dóczi T: Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas. Diagn Pathol 2012, 7:8. BioMed Central Full Text
• [5]Gulati S, Ytterhus B, Granli US, Gulati M, Lydersen S, Torp SH: Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas. Diagn Pathol 2010, 5:18. BioMed Central Full Text
• [6]Moro-Rodríguez E, Figols J, Alvira M, Uranga-Ocio JA, García-Poblete E: GFAP and alpha1a-AR staining and nuclear morphometry of oligodendrogliomas by confocal microscopy and image analysis: useful parameters for predicting survival in oligodendrogliomas. Diagn Pathol 2008, 3(1):S26. BioMed Central Full Text
• [7]Truong LN, Patil S, Martin SS, LeBlanc JF, Nanda A, Nordberg ML, Beckner ME: Rapid Detection of high-level oncogene amplifications in ultrasonic surgical aspirations of brain tumors. Diagn Pathol 2012, 7:66. BioMed Central Full Text
• [8]Wang Q, Deng J, Yuan J, Wang L, Zhao Z, He S, Zhang Y, Tu Y: Oncogenic reg IV is a novel prognostic marker for glioma patient survival. Diagn Pathol 2012, 7:69. BioMed Central Full Text
• [9]Curran WJ Jr, Scott CB: Radiosurgery for glioma patients: hope or hype? Int J Radiat Oncol Biol Phys 1996, 36:1279-1280.
• [10]Ambros V: The functions of animal microRNAs. Nature 2004, 431:350-355.
• [11]Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
• [12]de Moor CH, Meijer H, Lissenden S: Mechanisms of translational control by the 3′ UTR in development and differentiation. Semin Cell Dev Biol 2005, 16:49-58.
• [13]Cho WC: OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 2007, 6:60. BioMed Central Full Text
• [14]Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, Liu YP, van Duijse J, Drost J, Griekspoor A, Zlotorynski E, Yabuta N, De Vita G, Nojima H, Looijenga LH, Agami R: A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Adv Exp Med Biol 2007, 604:17-46.
• [15]Shu M, Zhou Y, Zhu W, Zhang H, Wu S, Chen J, Yan G: MicroRNA 335 is required for differentiation of malignant glioma cells induced by activation of cAMP/protein kinase A pathway. Mol Pharmacol 2012, 81:292-298.
• [16]Teplyuk NM, Mollenhauer B, Gabriely G, Giese A, Kim E, Smolsky M, Kim RY, Saria MG, Pastorino S, Kesari S, Krichevsky AM: MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol 2012, 14:689-700.
• [17]Cho WJ, Shin JM, Kim JS, Lee MR, Hong KS, Lee JH, Koo KH, Park JW, Kim KS: miR-372 regulates cell cycle and apoptosis of ags human gastric cancer cell line through direct regulation of LATS2. Mol Cells 2009, 28:521-527.
• [18]Wang D, Qiu C, Zhang H, Wang J, Cui Q: Human microRNA oncogenes and tumor suppressors show significantly different biological patterns: from functions to targets. PLoS One 2010, 5:e13067.
• [19]Chu SH, Ma YB, Feng DF, Zhang H, Zhu ZA, Li ZQ, Jiang PC: Correlation of low SLC22A18 expression with poor prognosis in patients with glioma. J Clin Neurosci 2012, 19:95-98.
• [20]Nikaki A, Piperi C, Papavassiliou AG: Role of microRNAs in gliomagenesis: targeting miRNAs in glioblastoma multiforme therapy. Expert Opin Investig Drugs 2012, 21:1475-1488.
• [21]Yamashita S, Yamamoto H, Mimori K, Nishida N, Takahashi H, Haraguchi N, Tanaka F, Shibata K, Sekimoto M, Ishii H, Doki Y, Mori M: MicroRNA-372 is associated with poor prognosis in colorectal cancer. Oncology 2012, 82:205-212.
• [22]Tian RQ, Wang XH, Hou LJ, Jia WH, Yang Q, Li YX, Liu M, Li X, Tang H: MicroRNA-372 is down-regulated and targets cyclin-dependent kinase 2 (CDK2) and cyclin A1 in human cervical cancer, which may contribute to tumorigenesis. J Biol Chem 2011, 286:25556-25563.